TY - JOUR
T1 - Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis
AU - Nuermberger, Eric L.
AU - Yoshimatsu, Tetsuyuki
AU - Tyagi, Sandeep
AU - Williams, Kathy
AU - Rosenthal, Ian
AU - O'Brien, Richard J.
AU - Vernon, Andrew A.
AU - Chaisson, Richard E.
AU - Bishai, William R.
AU - Grosset, Jacques H.
PY - 2004/11/15
Y1 - 2004/11/15
N2 - In a recent experimental study using the mouse model of tuberculosis, treatment with a combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative lung cultures by up to 2 months compared with the standard regimen of rifampin, isoniazid, and pyrazinamide. To confirm that this substitution of moxifloxacin for isoniazid permits a shorter duration of treatment, a second study was performed in which mice were assessed for relapse after treatment with combination therapy for 3, 4, 5, or 6 months. Although no relapse was observed among mice treated for at least 4 months with rifampin, moxifloxacin, and pyrazinamide, mice treated with rifampin, isoniazid, and pyrazinamide required 6 months of treatment before no relapse could be detected. For mice treated with rifampin, moxifloxacin, and pyrazinamide, similar efficacy was noted whether pyrazinamide was administered for 1 month, 2 months, or the entire duration of therapy. These results suggest that the use of rifampin, moxifloxacin, and pyrazinamide may substantially shorten the duration of therapy needed to cure human tuberculosis and that the full benefit of pyrazinamide in this regimen may be realized after just 1 month of treatment.
AB - In a recent experimental study using the mouse model of tuberculosis, treatment with a combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative lung cultures by up to 2 months compared with the standard regimen of rifampin, isoniazid, and pyrazinamide. To confirm that this substitution of moxifloxacin for isoniazid permits a shorter duration of treatment, a second study was performed in which mice were assessed for relapse after treatment with combination therapy for 3, 4, 5, or 6 months. Although no relapse was observed among mice treated for at least 4 months with rifampin, moxifloxacin, and pyrazinamide, mice treated with rifampin, isoniazid, and pyrazinamide required 6 months of treatment before no relapse could be detected. For mice treated with rifampin, moxifloxacin, and pyrazinamide, similar efficacy was noted whether pyrazinamide was administered for 1 month, 2 months, or the entire duration of therapy. These results suggest that the use of rifampin, moxifloxacin, and pyrazinamide may substantially shorten the duration of therapy needed to cure human tuberculosis and that the full benefit of pyrazinamide in this regimen may be realized after just 1 month of treatment.
KW - Fluoroquinolone
KW - Mouse
KW - Moxifloxacin
KW - Pyrazinamide
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=8444223157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8444223157&partnerID=8YFLogxK
U2 - 10.1164/rccm.200407-885OC
DO - 10.1164/rccm.200407-885OC
M3 - Article
C2 - 15306535
AN - SCOPUS:8444223157
SN - 1073-449X
VL - 170
SP - 1131
EP - 1134
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 10
ER -